Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dusan Ruzic

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 24, 2021
Fragment-Based Drug Design of Selective HDAC6 InhibitorsDusan Ruzic, Nemanja Djokovic, Katarina Nikolic
Anti-Cancer Agents in Medicinal Chemistry|May 19, 2026
Computational Design, Synthesis, and In Vitro Evaluation of Novel Piperazine-Based HDAC Inhibitors as Potential Breast Cancer TherapeuticsSehija Dizdarevic, Dusan Ruzic, Tatjana Srdic-Radic, et al.
Computational Biology and Chemistry|June 18, 2025
A computational framework for the design and development of ERK2 and multi-target ERK2/HDAC inhibitorsAlen Cebzan, Dusan Ruzic, Nemanja Djokovic, et al.
Journal of Biomolecular Structure & Dynamics|March 7, 2020
<i>In silico</i> identification of novel 5-HT<sub>2A</sub> antagonists supported with ligand- and target-based drug design methodologiesMilica Radan, Dusan Ruzic, Mirjana Antonijevic, et al.
Molecular Informatics|January 12, 2019
Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 InhibitorsDusan Ruzic, Milos Petkovic, Danica Agbaba, et al.
Frontiers in Chemistry|January 24, 2020
<i>In silico</i> Methods for Design of Kinase Inhibitors as Anticancer DrugsZarko Gagic, Dusan Ruzic, Nemanja Djokovic, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 13, 2016
Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein columnSlavica Filipic, Dusan Ruzic, Jelica Vucicevic, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic CarcinomaNemanja Djokovic, Ana Djuric, Dusan Ruzic, et al.
Journal of Biomolecular Structure & Dynamics|August 7, 2019
Structure-based design of selective histone deacetylase 6 zinc binding groupsLeandro A Alves Avelar, Dusan Ruzic, Nemanja Djokovic, et al.
Pharmaceutics|January 21, 2022
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionDusan Ruzic, Nemanja Djoković, Tatjana Srdić-Rajić, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|March 24, 2021
Fragment-Based Drug Design of Selective HDAC6 InhibitorsDusan Ruzic, Nemanja Djokovic, Katarina Nikolic
Anti-Cancer Agents in Medicinal Chemistry|May 19, 2026
Computational Design, Synthesis, and In Vitro Evaluation of Novel Piperazine-Based HDAC Inhibitors as Potential Breast Cancer TherapeuticsSehija Dizdarevic, Dusan Ruzic, Tatjana Srdic-Radic, et al.
Computational Biology and Chemistry|June 18, 2025
A computational framework for the design and development of ERK2 and multi-target ERK2/HDAC inhibitorsAlen Cebzan, Dusan Ruzic, Nemanja Djokovic, et al.
Journal of Biomolecular Structure & Dynamics|March 7, 2020
<i>In silico</i> identification of novel 5-HT<sub>2A</sub> antagonists supported with ligand- and target-based drug design methodologiesMilica Radan, Dusan Ruzic, Mirjana Antonijevic, et al.
Molecular Informatics|January 12, 2019
Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 InhibitorsDusan Ruzic, Milos Petkovic, Danica Agbaba, et al.
Frontiers in Chemistry|January 24, 2020
<i>In silico</i> Methods for Design of Kinase Inhibitors as Anticancer DrugsZarko Gagic, Dusan Ruzic, Nemanja Djokovic, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 13, 2016
Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein columnSlavica Filipic, Dusan Ruzic, Jelica Vucicevic, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic CarcinomaNemanja Djokovic, Ana Djuric, Dusan Ruzic, et al.
Journal of Biomolecular Structure & Dynamics|August 7, 2019
Structure-based design of selective histone deacetylase 6 zinc binding groupsLeandro A Alves Avelar, Dusan Ruzic, Nemanja Djokovic, et al.
Pharmaceutics|January 21, 2022
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionDusan Ruzic, Nemanja Djoković, Tatjana Srdić-Rajić, et al.
Pageof 3